Subscribe to the SLI Medical mailing list to receive updates on new arrivals, special offers and our promotions.
The store will not work correctly in the case when cookies are disabled.
Get Up to 25% OFF PPE MasksGowns * Limited time only.
SLI MEDICAL IS A WHOLESALE SITE! WE ONLY SELL TO QUALIFIED FACILITIES (Such As Hospitals, Physician Offices, & Distributors). All Addresses are Verified.
(25) Vials of Reagent Solution with 340 µL Salt Solution
Reading Type
(25) Sterile Nasal Swabs
Sample Type
SARS Positive Control Swab
Test Format
Negative Control Swab
Test Method
Package Insert
Test Name
and Procedure Card
Time to Results
25 Tests
UNSPSC Code
SLI Medical Acceptable Dating: we will ship >= 30 days
Visual Read
Nasal Swab Sample
Test Strip Format
Lateral Flow Method
SARS Antigen
10 Minute Results
41116144
Features
For use under an Emergency Use Authorization (EUA) only: https:www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
Product ships from McKesson with minimum 30 days dating
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
42 U.S.C. §263a
that meet the requirements to perform moderate
high or waived complexity tests; this test is authorized for use at the Point of Care (POC)
i.e.
in patient care settings operating under a CLIA Certificate of Waiver
Certificate of Compliance
or Certificate of Accreditation
Please see attached letter for detailed information on a 1 year extension on expiration dating
The QuickVue SARS Antigen Test is a lateral flow immunoassay that allows for the rapid
qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nares (NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms
The QuickVue SARS Antigen test does not differentiate between SARS-CoV and SARS-CoV-2
Positive results indicate the presence of viral antigens
but clinical correlation with patient history and other diagnostic information is necessary to determine infection status; positive results do not rule out bacterial infection or co-infection with other viruses
Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
Negative results should be treated as presumptive and confirmation with a molecular assay
if necessary
for patient management
may be performed; negative results do not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions
including infection control decisions
Negative results should be considered in the context of a patient’s recent exposures
history and the presence of clinical signs and symptoms consistent with COVID-19
The QuickVue SARS Antigen test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings
Accurate detection with direct anterior nares swab samples: 96.6% PPA and 99.3% NPA
Simple workflow follows a similar format to CLIA-waved QuickVue assays
just sample
dip
and read
Each kit contains everything needed to perform the test
including Nasal Swabs and positive and negative controls
TEST KIT, SARS ANTIGEN QUICKVUE PROFESSIONAL USE (25/KT)